Cryopreserved allogeneic Treg infusions associated with slowed disease progression and decreased plasma neurofilament level in ALS ...

MARSEILLE, France I April 22, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January ...

First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer ...

TAIPEI, Taiwan I April 22, 2025 I AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of ...

ALAMEDA, CA, USA and TAIPEI, Taiwan I April 21, 2025 I Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its ...

OSAKA, Japan I April 21, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has ...

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development. La Merie Publishing offers an e-mail notification service about the release of new products ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Today’s approval of Blenrep combinations in the UK is a transformative milestone for patients with multiple myeloma, a ...